The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP)
The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP)
复制标题
DOI：
10.1007/s11064-017-2275-z
复制
发表时间：
2017-07-01
影响因子：
4.4
通讯作者：
Sharma, Shalini
中科院分区：
文献类型：
--
作者：
Kehne, John H.;Klein, Brian D.;Sharma, Shalini
40多年来，国家神经疾病和中风研究所/国家卫生研究院资助的抗惊厥药物筛选计划为世界各地的参与者提供了临床前筛查服务，帮助识别/表征新的抗癫痫化合物，其中一些化合物已进入市场，用于治疗癫痫。新更名的癫痫治疗筛查计划(ETSP)有一个重新定位的使命，即寻找新的药物，这将有助于解决癫痫方面相当大的未得到满足的医疗需求。这些措施包括确定治疗难治性癫痫的抗癫痫药，以及将防止癫痫发展的抗癫痫药，或将改善甚至治愈已确定的癫痫及其共病的疾病改良剂。这份手稿概述了ETSP的努力，旨在确定下一代治疗剂，以进一步减轻癫痫的痛苦和负担。
For over 40 years, the National Institute of Neurological Disorders and Stroke/National Institutes of Health-funded Anticonvulsant Screening Program has provided a preclinical screening service for participants world-wide that helped identify/characterize new antiseizure compounds, a number of which advanced to the market for the treatment of epilepsy. The newly-renamed Epilepsy Therapy Screening Program (ETSP) has a refocused mission to identify novel agents which will help address the considerable remaining unmet medical needs in epilepsy. These include identifying antiseizure agents for treatment-resistant epilepsy, as well as anti-epileptogenic agents that will prevent the development of epilepsy or disease-modifying agents that will ameliorate or even cure established epilepsy and its comorbidities. This manuscript provides an overview of the ETSP's efforts aimed at identifying the next generation of therapeutic agents to further reduce the suffering from and burden of epilepsy.